Haemonetics (NYSE:HAE) Releases FY 2025 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.500-4.700 for the period, compared to the consensus estimate of 4.590. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Ratings Changes

A number of analysts recently issued reports on HAE shares. Needham & Company LLC restated a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a research note on Tuesday, December 3rd. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price for the company. Barrington Research reissued an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a research report on Wednesday, December 4th. Finally, Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $108.78.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $71.26 on Thursday. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The firm’s 50 day moving average is $77.77 and its two-hundred day moving average is $78.79. The firm has a market capitalization of $3.58 billion, a P/E ratio of 29.57, a PEG ratio of 1.07 and a beta of 0.39. Haemonetics has a 52 week low of $65.73 and a 52 week high of $97.97.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business had revenue of $345.50 million for the quarter, compared to analysts’ expectations of $342.57 million. During the same period in the previous year, the business earned $0.99 earnings per share. The company’s revenue was up 8.6% on a year-over-year basis. Analysts anticipate that Haemonetics will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.